Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 7Fallopian Tube Neoplasms 6Carcinoma 2Sarcoma, Endometrial Stromal 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Kidney Neoplasms 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 7Cisplatin 6pembrolizumab 5Carboplatin 5Bevacizumab 5liposomal doxorubicin 3Gemcitabine 3trebananib 2niraparib 2interferon gamma-1b 2dostarlimab 2catumaxomab 2atezolizumab 2anlotinib 2Topotecan 2Radiotherapy, Intensity-Modulated 2Ocoxin 2Itraconazole 2Injections 2Hyperthermic Intraperitoneal Chemotherapy 2Drug Therapy 2Docetaxel 2vosaroxin 1vistusertib 1pertuzumab 1peginterferon alfa-2b 1olaparib 1nintedanib 1lanreotide 1epothilone B 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma × trebananib × Gynecologic × Clear all
NCT01253681 2015-10-14

Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer

Amgen

Phase 1 Completed
27 enrolled
Gynecologic

Carcinoma, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00770536 2015-09-29

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

Amgen

Phase 1 Completed
103 enrolled
Gynecologic

Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡